Klein M, Heimans J J, Aaronson N K, van der Ploeg H M, Grit J, Muller M, Postma T J, Mooij J J, Boerman R H, Beute G N, Ossenkoppele G J, van Imhoff G W, Dekker A W, Jolles J, Slotman B J, Struikmans H, Taphoorn M J B
Department of Medical Psychology, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands.
Lancet. 2002 Nov 2;360(9343):1361-8. doi: 10.1016/s0140-6736(02)11398-5.
Because survival benefits of treatment with radiotherapy are questionable and such treatment can cause substantial damage to the brain over time, the optimum management strategy for low-grade gliomas remains controversial. We aimed to identify the specific effects of radiotherapy on objective and self-reported cognitive function, and on cognitive deterioration over time, in patients with low-grade gliomas treated with early radiotherapy.
195 patients with low-grade glioma (of whom 104 had received radiotherapy 1-22 years previously) were compared with 100 low-grade haematological patients and 195 healthy controls. Our analyses aimed to differentiate between the effects of the tumour (eg, disease duration, lateralisation) and treatment effects (neurosurgery, radiotherapy, antiepileptic drugs) on cognitive function and on relative risk of cognitive disability.
Low-grade glioma patients had lower ability in all cognitive domains than did low-grade haematological patients, and did even less well by comparison with healthy controls. Use of radiotherapy was associated with poorer cognitive function; however, cognitive disability in the memory domain was found only in radiotherapy patients who received fraction doses exceeding 2 Gy. Antiepileptic drug use was strongly associated with disability in attentional and executive function.
Our findings suggest that the tumour itself has the most deleterious effect on cognitive function and that radiotherapy mainly results in additional long-term cognitive disability when high fraction doses are used. Additionally, the effects of other medical factors, especially antiepileptic drug use, on cognitive function in glioma patients deserve attention.
由于放射治疗的生存获益存在疑问,且随着时间推移这种治疗会对大脑造成实质性损害,因此低级别胶质瘤的最佳管理策略仍存在争议。我们旨在确定早期接受放射治疗的低级别胶质瘤患者中,放疗对客观和自我报告的认知功能以及随时间推移的认知衰退的具体影响。
将195例低级别胶质瘤患者(其中104例在1 - 22年前接受过放疗)与100例低级别血液系统疾病患者及195名健康对照者进行比较。我们的分析旨在区分肿瘤(如疾病持续时间、病变侧别)和治疗因素(神经外科手术、放疗、抗癫痫药物)对认知功能及认知障碍相对风险的影响。
低级别胶质瘤患者在所有认知领域的能力均低于低级别血液系统疾病患者,与健康对照者相比差距更大。放疗的使用与较差的认知功能相关;然而,仅在接受分割剂量超过2 Gy的放疗患者中发现记忆领域的认知障碍。抗癫痫药物的使用与注意力和执行功能障碍密切相关。
我们的研究结果表明,肿瘤本身对认知功能的损害最大,高分割剂量放疗主要导致额外的长期认知障碍。此外,其他医学因素,尤其是抗癫痫药物的使用,对胶质瘤患者认知功能的影响值得关注。